Dyne Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 2, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 2, 2026

DYN$18.62+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
(in thousands, except share and per share data)	2025	2024
Assets
Current assets:
Cash and cash equivalents	$893,369	$435,449
Marketable securities	217,193	206,819
Prepaid expenses and other current assets	16,025	17,011
Total current assets	1,126,587	659,279
Property and equipment, net	24,029	5,398
Right-of-use assets	20,742	24,615
Restricted cash and other assets	15,600	1,942
Total assets	$1,186,958	$691,234
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$8,082	$6,562
Accrued expenses and other current liabilities	37,548	30,846
Lease liabilities	4,995	4,850
Total current liabilities	50,625	42,258
Long-term debt, net	148,921	—
Lease liabilities, net of current portion	15,283	19,138
Total liabilities	214,829	61,396
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024	—	—
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2025 and 2024; 164,950,540 and 102,318,629 shares issued and outstanding at December 31, 2025 and 2024, respectively	16	10
Additional paid-in capital	2,367,780	1,579,750
Accumulated other comprehensive gain	475	6
Accumulated deficit	(1,396,142)	(949,928)
Total stockholders’ equity	972,129	629,838
Total liabilities and stockholders’ equity	$1,186,958	$691,234

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.